FGF2 and neoplasm: The low survival rate of CRC patients is principally due to the chemotherapeutic resistance of tumor cells; relatedly, it has been reported that bFGF could regulate the epigenetic mechanisms of drug resistance, thus representing a novel potential target for improving the sensitivity of tumor cells to chemotherapeutic agents [102].